RecruitingNCT07313462
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Sponsor
University Hospital, Strasbourg, France
Enrollment
830 participants
Start Date
Feb 7, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
Eligibility
Min Age: 50 Years
Inclusion Criteria4
- Patients with RRMS onset after age 50
- Patients who started their first disease-modifying therapy within 2 years of the first symptoms
- Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
- Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
Exclusion Criteria1
- \- Patients with early progressive MS
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07313462
Related Trials
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
NCT053596531 location
Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences
NCT048197371 location
Effect of Music Therapy on Pain in People With Multiple Sclerosis
NCT068001441 location
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
NCT056338751 location
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
NCT041214681 location